Induction therapy after cardiac transplantation: A comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection
Authors:
- 31 March 2005
- journal article
- research article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (3) , 296-302
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumabThe Journal of Heart and Lung Transplantation, 2001
- DaclizumabBioDrugs, 2001
- Daclizumab (Zenapax®) inhibits early interleukin-2 receptor signal transduction eventsTransplant Immunology, 2000
- Immunosuppression induction with rabbit antithymocyte globulin in heart transplantation patients: 6-year experience at the Sheba Medical CenterTransplantation Proceedings, 2000
- Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal AntibodyNew England Journal of Medicine, 2000
- Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host diseaseBlood, 2000
- A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantationThe Journal of Heart and Lung Transplantation, 1999
- Current use of polyclonal antilymphocyte antibody preparationsTransplantation Proceedings, 1999
- BLOCKADE OF THE INTERLEUKIN (IL)-2/IL-2 RECEPTOR PATHWAY WITH A MONOCLONAL ANTI-IL-2 RECEPTOR ANTIBODY (BT563) DOES NOT PREVENT THE DEVELOPMENT OF ACUTE HEART ALLOGRAFT REJECTION IN HUMANSTransplantation, 1998
- Cytomegalovirus Infection Rate among Heart Transplant Patients in Relation to Anti-thymocyte Immunoglobulin Induction TherapyScandinavian Journal of Infectious Diseases, 1994